It’s been nearly 25 years since the first pink ribbon was worn for breast cancer. Over the past few decades, there have been significant improvements in the outcomes and survival rates for women with this disease. But breast cancer is still far from defeated. Over 130,000 women die from breast cancer every year in Europe, and incidence and mortality are still rising in many European countries.
"When I was diagnosed with metastatic breast cancer (…), I was given 6 to 9 months to live. In 3 months, I will have had metastatic disease for 4 years."
A woman with MBC
One group of breast-cancer patients, in particular, continues to face a profound struggle in dealing with the illness. Metastatic breast cancer (MBC), the most advanced form of breast cancer, has no cure. Treatment may significantly help MBC patients maintain their quality of life for as long as possible, by delaying the disease’s progression and minimizing its symptoms.
The “Breast Cancer Matters” website, presented by Pfizer, aims to improve the public’s understanding of MBC and outline the unmet needs of European women who have the disease. We will do so by:
- sharing the stories of inspiring members of the breast-cancer and metastatic breast-cancer communities, from patients and patient advocates to clinical experts and policy advisors
- enhancing the BC/MBC conversation on multiple platforms
- providing stakeholders with information and continual updates from the breast-cancer policy and advocacy domains
- bringing individual experiences and political initiatives together to draw a comprehensive picture of the current state of MBC in Europe.